The global bioprinting market is projected to grow from $2.1 billion in 2024 to $5.1 billion by 2030, at a compound annual growth rate of 16.1% over the 2025–2030 forecast period, according to BCC Research. Growth is underpinned by demand for tissue-engineered constructs in regenerative medicine and pharmaceutical drug discovery, alongside the organ donor shortage and advances in bioinks, multi-printhead systems, AI workflows, 4D and magnetic bioprinting, organ-on-chip devices, dECM bioinks and iPSCs. North America leads with about 38.0% market share. Pharmaceutical firms are adopting bioprinted 3D tissue models to improve preclinical accuracy and reduce animal testing amid regulatory shifts in the U.S., EU and India. Key players include BICO Group AB (CELLINK), 3D Systems, Merck KGaA, Organovo, Aspect Biosystems and others. Near-term risks include low cell viability in extrusion printing, high dECM bioink costs, IP uncertainty, regulatory delays and the challenge of fabricating vascularized tissue at scale.